Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury
Year: 2014
Type: article
Abstract: Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. An estimated 1.7 million injuries occur within the USA each year and 10 million people are affected annually worldwide. Indeed, nearly one third (30.5%) of all injury-related deaths in the USA are associated with TBI, which will soon outpace many common diseases as the major cause of death and disability. Associated with a high morbidity and mortality and no specific therapeutic treatment, TBI has become a pressing public health and medical problem. The highest incidence of TBI occurs in young adults (15-24 years age) and in the elderly (≥75 years of age). Older individuals are particularly vulnerable to these types of injury, often associated with falls, and have shown increased mortality and worse functional outcome after lower initial injury severity. In addition, a new and growing form of TBI, blast injury, associated with the detonation of improvised explosive devices in the war theaters of Iraq and Afghanistan, are inflicting a wave of unique casualties of immediate impact to both military personnel and civilians, for which long-term consequences remain unknown and may potentially be catastrophic. The neuropathology underpinning head injury is becoming increasingly better understood. Depending on severity, TBI induces immediate neuropathologic effects that, for the mildest form, may be transient; however, with increasing severity, these injuries cause cumulative neural damage and degeneration. Even with mild TBI, which represents the majority of cases, a broad spectrum of neurologic deficits, including cognitive impairments, can manifest that may significantly influence quality of life. Further, TBI can act as a conduit to longer term neurodegenerative disorders. Prior studies of glucagon-like peptide-1 (GLP-1) and long-acting GLP-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (Alzheimer's and Parkinson's diseases) and acute cerebrovascular (stroke) disorders. In view of the mechanisms underpinning these disorders as well as TBI, we review the literature and recent studies assessing GLP-1 receptor agonists as a potential treatment strategy for mild to moderate TBI.
Source: Alzheimer s & Dementia
Institutions: National Institutes of Health, National Institute on Aging, Tel Aviv University, Tel Aviv Sourasky Medical Center, Taipei Medical University Hospital, Taipei Medical University, Case Western Reserve University, Indiana University Indianapolis, Indiana University School of Medicine, Medical University of South Carolina
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Cholesterol and amyloidogenesis, G2228885865, Understanding the Neuroprotective Activities of Posiphen, Cholinesterase Inhibitors in Alzheimer's Disease, Human MicroRNA as a potential therapeutic target in Alzheimer's disease., Dietary modification of Alzheimer's biomarkers, Novel regulation of APP and beta-secretase (BACE) in Alzheimer’s disease, G7423759087, Regulation of APP Pathway Gene Promoters in Alzheimer's, ALZHEIMERS RESEARCH PROJECT: Neuroprotective role of GLP-1 receptor agonists (Neurodegenerative disorders & Alzheimer's disease)
OpenAlex ID: W2025865178
